Company Profiles

driven by the PitchBook Platform

Symphogen

Description

Developer of recombinant polyclonal antibodies designed to treat and prevent infectious diseases and cancer. The company's recombinant polyclonal antibodies include Sym001, a recombinant polyclonal antibody composition for the treatment of idiopathic thrombocytopenic purpura and the prevention of hemolytic disease in newborns and Sym002, which includes recombinant polyclonal anti-vaccine virus antibodies to treat the adverse reactions caused by smallpox vaccinations, enabling cancer patients to begin treatment more quickly, resulting in a higher likelihood of a successful treatment.

2000

Founded

PRIVATE

Status

51-200

Employees

Conv. Debt

Latest Deal Type

$75.8M

Latest Deal Amount

$374M

Total Amount Raised

Description

Developer of recombinant polyclonal antibodies designed to treat and prevent infectious diseases and cancer. The company's recombinant polyclonal antibodies include Sym001, a recombinant polyclonal antibody composition for the treatment of idiopathic thrombocytopenic purpura and the prevention of hemolytic disease in newborns and Sym002, which includes recombinant polyclonal anti-vaccine virus antibodies to treat the adverse reactions caused by smallpox vaccinations, enabling cancer patients to begin treatment more quickly, resulting in a higher likelihood of a successful treatment.

Website:

www.symphogen.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery

Primary Office

Pederstrupvej 93 2750 BallerupDenmark +45 4526 5050
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Symphogen's full profile, request a free trial.

Symphogen Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Symphogen Investors (15)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Danica PensionOtherMinority000 0000000 0000
Danske Private EquityFund of FundsMinority000 0000000 0000
EW Healthcare PartnersGrowth/ExpansionMinority000 0000000 0000
GenentechCorporationMinority000 0000000 0000
Gilde Healthcare PartnersVenture CapitalMinority000 0000000 0000
Danica Pension Other
Danske Private Equity Fund of Funds
EW Healthcare Partners Growth/Expansion
Genentech Corporation
Gilde Healthcare Partners Venture Capital

Symphogen Executive Team (13)

NameTitleBoard
Seat
Contact
Info
Martin OlinChief Executive Officer
Jesper BrammingChief Financial Officer
Gayle MillsChief Business Officer
Ivan Horak MDChief Scientific & Medical Officer and Head of Global Research & Development
Kirsten Drejer Ph.DCo-Founder, Executive Director and Board Member
Martin Olin Chief Executive Officer
Jesper Bramming Chief Financial Officer
Gayle Mills Chief Business Officer
Ivan Horak MD Chief Scientific & Medical Officer and Head of Global Research & Development
Kirsten Drejer Ph.D Co-Founder, Executive Director and Board Member

Symphogen Board Members (13)

NameRepresentingRoleSinceContact
Info
Aleks Engel Ph.DNovoDirector, Large Investments000 0000
Annika EspanderSelfBoard Member000 0000
Annika JanssonSelfBoard Member000 0000
Anthony Tolcher MDSelfBoard Member000 0000
Arthur FrankenGilde Healthcare PartnersPartner000 0000
Aleks Engel Ph.D Director, Large Investments Novo
Annika Espander Board Member Self
Annika Jansson Board Member Self
Anthony Tolcher MD Board Member Self
Arthur Franken Partner Gilde Healthcare Partners
Request full access to PitchBook